NYSE · SOLVHealthcareSurgical Instruments

Solventum financials

$89.32−0.25%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
Revenue$8.32B$8.25B
Gross profit$4.45B$4.59B
Gross margin53.5%55.6%
Operating income$632.0M$1.04B
Net income$1.56B$479.0M
Net margin18.7%5.8%
Diluted EPS$8.88$2.76
EBITDA$1.12B$1.59B
Operating cash flow$369.0M$1.19B
Free cash flow-$10.0M$805.0M
Diluted shares175.3M173.7M

Balance sheet

Period endDec 31Dec 31
Cash & equivalents$878.0M$762.0M
Short-term investments$0.00$0.00
Total debt$5.04B$8.01B
Total assets$14.29B$14.46B
Total liabilities$9.24B$11.50B
Shareholders' equity$5.05B$2.96B

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology